BioNTech will work with Scancell to discover and characterize T cell receptors and has an option to form a license agreement for the therapeutics.

The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and sees Sanofi obtain worldwide rights to fitusiran.

The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.

Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.

At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.

Breakout Labs has backed over 30 companies since it handed out the first batch of grants in 2012.